Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check3 days agoChange DetectedPublications section text was updated to clarify auto-fill from PubMed, and the revision/version numbers were updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check10 days agoChange DetectedRemoved the government funding lapse notice from the study page, which previously directed users to official status pages for operating updates.SummaryDifference0.4%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedNew entries appear in the Study Record Dates showing Results First Submitted (2024-05-13), Results First Submitted that Met QC Criteria (2025-01-07), and Results First Posted (2025-02-03).SummaryDifference0.5%

- Check53 days agoChange Detected- Added a government operating status notice and a version bump to v3.2.0. - Removed the old version tag v3.1.0.SummaryDifference4%

- Check61 days agoChange DetectedAdded new oncology-related terms and upgraded revision to v3.1.0; removed the Liver Cancer topic and old v3.0.2 revision.SummaryDifference1%

- Check75 days agoChange DetectedUpdated to Revision: v3.0.2. Removed the Back to Top element.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.